Finance And Related Services Tenders

Various Open House Contracts 2023

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Nitisinone (A16ax04) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Apremilast (L04aa32) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Aclidinium Bromide (R03bb05) as Part of a So-Called Open House Model.

Open House Original Discount Contracts 2023-26 - Fingolimod (Potency 0.5Mg)

Open House Original Discount Agreements 2023-13 - Tacrolimus (Prolonged-Release Tablet and Granule Formulations for Oral Suspension Dosage Forms)

Conclusion of a Non-Exclusive Framework Contract for Building Inspections According to Din 1076 in the Open House Procedure of the West Branch, Published in 2023

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Ixekizumab, Atc Code: L04ac13 for the Period from September 1St, 2023 to August 31St, 2025